Sastasundar Ventures
328.35
+5.70(+1.77%)
Market Cap₹1,044.50 Cr
PE Ratio-112.32
Company Performance:
1D+1.77%
1M+9.49%
6M+21.21%
1Y+8.06%
5Y+144.85%
View Company Insightsright
More news about Sastasundar Ventures
12Aug 25
Sastasundar Ventures Reports Robust Q1 Profit, Driven by Strong Healthcare Network Performance
Sastasundar Ventures Limited reported a consolidated net profit of Rs. 2,659.21 crore in Q1, a significant improvement from last year's loss. Total revenue from operations stood at Rs. 298.43 crore. The Healthcare Network segment contributed Rs. 278.54 crore to revenue but reported a loss, while the Financial Services segment generated Rs. 19.89 crore in revenue with a profit. On a standalone basis, the company reported a revenue of Rs. 9.67 lakh and a reduced net loss of Rs. 10.95 lakh. The Board of Directors also reviewed and amended the company's fair disclosure practices code.
30May 25
SASTASUNDAR VENTURES Reports Decline in Q4 Profit and Revenue
SASTASUNDAR VENTURES released its Q4 consolidated financial results, showing a decline in both profit and revenue. Net profit decreased by 16.46% to ₹137.00 crore from ₹164.00 crore in the previous year. Revenue fell by 7.17% to ₹285.00 crore from ₹307.00 crore year-over-year.
Sastasundar Ventures
328.35
+5.70
(+1.77%)
1 Year Returns:+8.06%
Industry Peers
Dr. Lal Path Labs
3,051.80
(-2.01%)
Metropolis Healthcare
1,931.00
(-0.16%)
Thyrocare Technologies
495.70
(-66.40%)
Krsnaa Diagnostics
810.75
(-0.52%)
Suraksha Diagnostic
292.70
(+0.81%)
3B BlackBio DX
1,286.30
(-0.92%)
Sastasundar Ventures
328.35
(+1.77%)
Chandan Healthcare
333.15
(-1.55%)